AI Article Synopsis
- Researchers developed a peptide-based immunotherapy called SynerGel, which is an injectable platform for delivering drugs directly into tumors.
- The system uses a hydrogel loaded with antitumor cyclic dinucleotide (CDN) to promote immune responses while slowing down drug release compared to traditional hydrogels.
- In animal studies, SynerGel significantly improved survival rates for mice with treatment-resistant oral tumors, with a median survival of 67.5 days versus 44 days for untreated controls.
Article Abstract
We evaluated a peptide-based immunotherapy termed SynerGel: an injectable, biomaterial-based platform for intratumoral drug delivery. A drug-mimicking peptide hydrogel named L-NIL-MDP was loaded with an antitumor cyclic dinucleotide (CDN) immunotherapy agonist. The biomaterial combines inducible nitric oxide synthase (iNOS) inhibition with controlled delivery of CDNs, demonstrating between 4- and 20-fold slower drug release than commercially available hydrogels. SynerGel allowed for immune-mediated elimination of established treatment-resistant oral tumors in a murine model, with a median survival of 67.5 days compared with 44 days in no-treatment control. This report details findings for a promising therapy showing improved efficacy over previous hydrogel systems.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8325389 | PMC |
| http://dx.doi.org/10.1021/acsbiomaterials.0c01575 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Immunomodulatory effect of PLGA-encapsulated mesenchymal stem cells-derived exosomes for the treatment of allergic rhinitis.
Front Immunol
July 2024
Department of ORL-HNS, Shanghai Fourth People's Hospital, School of Medicine, Tongji University, Shanghai, China.
Introduction: Allergic rhinitis (AR) is an upper airway inflammatory disease of the nasal mucosa. Conventional treatments such as symptomatic pharmacotherapy and allergen-specific immunotherapy have considerable limitations and drawbacks. As an emerging therapy with regenerative potential and immunomodulatory effect, mesenchymal stem cell-derived exosomes (MSC-Exos) have recently been trialed for the treatment of various inflammatory and autoimmune diseases.
View Article and Find Full Text PDFBiomaterial-Facilitated Immunotherapy for Established Oral Cancers.
ACS Biomater Sci Eng
February 2021
Department of Oral & Maxillofacial Surgery, The University of Texas Health Science Center at Houston School of Dentistry, Houston, Texas 77054, United States.
Article Synopsis
- Researchers developed a peptide-based immunotherapy called SynerGel, which is an injectable platform for delivering drugs directly into tumors.
- The system uses a hydrogel loaded with antitumor cyclic dinucleotide (CDN) to promote immune responses while slowing down drug release compared to traditional hydrogels.
- In animal studies, SynerGel significantly improved survival rates for mice with treatment-resistant oral tumors, with a median survival of 67.5 days versus 44 days for untreated controls.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!